Gilteritinib vs XY0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline

Gilteritinib

Marketed by Astellas Pharma

Approved in Acute Myeloid Leukemiasmall molecule
Partial signal

NCT02997202 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit.

Next expected readout: December 2026 · NCT06001788 (registry estimate)

Reported efficacy

Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) (missed)

Result source: NCT02752035

XY0206

Developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd

Phase 3 in Acute Myeloid Leukemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT05876832 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGilteritinibXY0206
OS, median9.8 vs 9.2vs AZAn 89NCT02752035
3 other results
—Trial running · NCT05876832
Complete remission21.1% vs 10.5%vs Salvage Chemotherapywk 24 · n 247NCT02421939
4 other results
  • 25.8% vs 17.5% n 89 · Phase 3 · secondary NCT02752035
  • 9.1% vs 17.5% n 22 · Phase 3 · secondary NCT02752035
  • 33.3% 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 0% 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
—Trial running · NCT05876832
Event-free survival, median0.0 vs 0.0vs AZAn 89NCT02752035
5 other results
  • 2.8 vs 0.7 n 189 · Phase 3 · secondary NCT02421939
  • 0.0 vs 0.0 n 22 · Phase 3 · secondary NCT02752035
  • 14.1 vs 6.7 n 63 · Phase 2 · secondary NCT02927262
  • 5.8 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 1.7 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
—Trial running · NCT05876832
Duration of response, median14.8 vs 1.8vs Salvage Chemotherapyn 52NCT02421939—Trial running · NCT05876832

OS, median

Gilteritinib
9.8 vs 9.2vs AZAn 89NCT02752035
3 other results
XY0206
—Trial running · NCT05876832

Complete remission

Gilteritinib
21.1% vs 10.5%vs Salvage Chemotherapywk 24 · n 247NCT02421939
4 other results
  • 25.8% vs 17.5% n 89 · Phase 3 · secondary NCT02752035
  • 9.1% vs 17.5% n 22 · Phase 3 · secondary NCT02752035
  • 33.3% 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 0% 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
XY0206
—Trial running · NCT05876832

Event-free survival, median

Gilteritinib
0.0 vs 0.0vs AZAn 89NCT02752035
5 other results
  • 2.8 vs 0.7 n 189 · Phase 3 · secondary NCT02421939
  • 0.0 vs 0.0 n 22 · Phase 3 · secondary NCT02752035
  • 14.1 vs 6.7 n 63 · Phase 2 · secondary NCT02927262
  • 5.8 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 1.7 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
XY0206
—Trial running · NCT05876832

Duration of response, median

Gilteritinib
14.8 vs 1.8vs Salvage Chemotherapyn 52NCT02421939
XY0206
—Trial running · NCT05876832
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

XY0206: no structured comparison results are available for Acute Myeloid Leukemia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Gilteritinib: 4 of 4 rows · XY0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGilteritinib
Dropout rate
31.5%a
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
—Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
n/a: no completion milestoneSafety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
100%
NCT02421939 · Phase 3
61.9%
NCT02927262 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
100%200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
—Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
6.7%Safety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
13%
NCT02421939 · Phase 3
11.1%
NCT02927262 · Phase 2 · registry result, not featured evidence
0%120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
12.5%120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
—200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
17.6%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
25%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20.6%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
7.2%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
9.5%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
13.3%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
Serious AEs
51.7%a
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
90.9%Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
92%Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
93.3%Safety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
85.8%
NCT02421939 · Phase 3
38.7%
NCT02927262 · Phase 2 · registry result, not featured evidence
100%120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
87.5%120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
0%200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
33.3%80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
82.4%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
92%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
33.3%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
78.8%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
90.5%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
92.3%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
chronic graft versus host disease 52.8% (placebo 43.5%)
acute graft versus host disease 37.6% (placebo 36.2%)
neutrophil count decreased 27.5% (placebo 9.6%)
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 24 more results
diarrhoea 40.9%
oedema peripheral 31.8%
vomiting 31.8%
NCT02752035 · Phase 3 · monotherapy
pyrexia 42%
constipation 39.8%
diarrhoea 34.1%
NCT02752035 · Phase 3 · combination
anaemia 53.3%
diarrhoea 46.7%
neutropenia 46.7%
NCT02752035 · Phase 3 · combination
anaemia 45.5%
alanine aminotransferase increased 40.7%
aspartate aminotransferase increased 39.4%
NCT02421939 · Phase 3
blood creatine phosphokinase increased 29% (placebo 2.9%)
neutrophil count decreased 19.4% (placebo 8.6%)
platelet count decreased 19.4% (placebo 11.4%)
NCT02927262 · Phase 2 · registry result, not featured evidence
120 mg + 420 mg
decreased appetite 100%
dizziness 100%
dyspnoea 100%
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
120 mg + 840 mg
diarrhoea 50%
fatigue 50%
nausea 50%
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
200 mg
benign breast neoplasm 100%
cough 100%
covid-19 100%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
120 mg
cough 66.7%
decreased appetite 66.7%
diarrhoea 66.7%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
80 mg
anorectal discomfort 33.3%
anxiety 33.3%
arthralgia 33.3%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
40 mg
cough 100%
muscle spasms 100%
abdominal discomfort 50%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
450 mg
aspartate aminotransferase increased 66.7%
hyperglycaemia 66.7%
abdominal pain 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
300 mg
pollakiuria 66.7%
alanine aminotransferase increased 33.3%
anaemia 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
300 mg
anaemia 35.3%
diarrhoea 29.4%
epistaxis 23.5%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
200 mg
fatigue 100%
abdominal pain 33.3%
aspartate aminotransferase increased 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
200 mg
diarrhoea 45%
aspartate aminotransferase increased 35%
anaemia 33%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
120 mg
constipation 66.7%
abdominal pain lower 33.3%
blood bilirubin increased 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
120 mg
anaemia 40.9%
diarrhoea 40.9%
fatigue 40.9%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
80 mg
decreased appetite 66.7%
nausea 66.7%
vomiting 66.7%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
80 mg
fatigue 38.1%
anaemia 33.3%
cough 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40 mg
constipation 33.3%
dizziness 33.3%
dry skin 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40 mg
dyspnoea 38.5%
fatigue 38.5%
anaemia 30.8%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20 mg
anaemia 40%
nausea 40%
abdominal pain 20%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20 mg
hypokalaemia 41.7%
fatigue 33.3%
oedema peripheral 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 37 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gilteritinib

Relapse-free Survival NA vs NA placebo months
time to event · months
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 1 more result
24.02 vs 15.84 placebo months
NCT02927262 · Phase 2 · registry result, not featured evidence
Overall Survival NA vs NA placebo months
time to event · months
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 4 more results
9.82 vs 9.23 AZA months
NCT02752035 · Phase 3 · combination
5.24 vs 9.23 AZA months
NCT02752035 · Phase 3 · monotherapy
9.3 vs 5.6 Salvage Chemotherapy months
NCT02421939 · Phase 3
NA vs NA placebo months
NCT02927262 · Phase 2 · registry result, not featured evidence
Non-Relapse Mortality 13.6% (n=178) vs 6.6% (n=178) placebo
responder rate · % of participants
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
Event-Free Survival NA vs NA placebo months
time to event · months
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 4 more results
0.03 vs 0.03 AZA months
NCT02752035 · Phase 3 · combination
0.03 vs 0.03 AZA months
NCT02752035 · Phase 3 · monotherapy
2.8 vs 0.7 Salvage Chemotherapy months
NCT02421939 · Phase 3
14.06 vs 6.74 placebo months
NCT02927262 · Phase 2 · registry result, not featured evidence
Relapse 12.4% (n=178) vs 26.7% (n=178) placebo
responder rate · % of participants
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
Complete Remission With Incomplete Platelet Recovery 6.7% (n=89) vs 0% (n=57) AZA
responder rate · % of participants
CRp
NCT02752035 · Phase 3 · combination
show 1 more result
18.2% (n=22) vs 0% (n=57) AZA
CRp
NCT02752035 · Phase 3 · monotherapy
Complete Remission With Incomplete Recovery 29.2% (n=89) vs 10.5% (n=57) AZA
responder rate · % of participants
CRi
NCT02752035 · Phase 3 · combination
show 1 more result
27.3% (n=22) vs 10.5% (n=57) AZA
CRi
NCT02752035 · Phase 3 · monotherapy
Complete Remission 25.8% (n=89) vs 17.5% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 2 more results
9.1% (n=22) vs 17.5% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
21.1% (n=247) vs 10.5% (n=124) Salvage Chemotherapy @ 24wk
NCT02421939 · Phase 3
CRc 61.8% (n=89) vs 28.1% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
54.5% (n=22) vs 28.1% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
CRh 10.1% (n=89) vs 1.8% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
22.7% (n=22) vs 1.8% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
CR or CRh 36% (n=89) vs 19.3% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
31.8% (n=22) vs 19.3% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
Transfusion Conversion 35.6% (n=73) vs 44.7% (n=38) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
61.1% (n=18) vs 44.7% (n=38) AZA
NCT02752035 · Phase 3 · monotherapy

+ 34 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gilteritinib's landscape · XY0206's landscape